Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of malignant plasma cells. patient outcome has improved markedly over the last decades due to the introduction of novel therapeutic agents such as bortezomib, thalidomide and lenalidomide. However, MM still remains largely incurable and patients eventually become refractory to available treatments. To address this unmet medical need, a variety of new molecules are currently being developed in preclinical models and/or are being investigated in clinical studies. Areas covered: We summarized available data on new investigational drugs showing anti-myeloma single-agent activity and that might have a role in the future therapeutic armamentarium against MM. Besides their single-agent activity, the synergic potential of these new agents with the currently approved drugs will be pivotal in their integration into consolidated MM backbone therapies. The drugs discussed include alkylators, new proteasome inhibitors, novel anti-CD38 monoclonal antibodies, Bcl-2 inhibitors, Cyclin-Dependent-Kinase inhibitor, Kinesin-spindle protein inhibitors, MEK1/2 inhibitors, AKT inhibitors and PIM-Kinase inhibitors. Expert opinion: Isatuximab, oprozomib, melflufen, venetoclax and filanesib seem to be the most promising agents with single agent activity. Nevertheless, lack of clinical activity as single agent does not imply clinical inefficacy in combination treatments.

Novel investigational drugs active as single agents in multiple myeloma

D'AGOSTINO, MATTIA
Co-first
;
SALVINI, MARCO
Co-first
;
PALUMBO, Antonio;LAROCCA, Alessandra;GAY, Francesca Maria
Last
2017-01-01

Abstract

Multiple myeloma (MM) is a hematologic malignancy characterized by proliferation of malignant plasma cells. patient outcome has improved markedly over the last decades due to the introduction of novel therapeutic agents such as bortezomib, thalidomide and lenalidomide. However, MM still remains largely incurable and patients eventually become refractory to available treatments. To address this unmet medical need, a variety of new molecules are currently being developed in preclinical models and/or are being investigated in clinical studies. Areas covered: We summarized available data on new investigational drugs showing anti-myeloma single-agent activity and that might have a role in the future therapeutic armamentarium against MM. Besides their single-agent activity, the synergic potential of these new agents with the currently approved drugs will be pivotal in their integration into consolidated MM backbone therapies. The drugs discussed include alkylators, new proteasome inhibitors, novel anti-CD38 monoclonal antibodies, Bcl-2 inhibitors, Cyclin-Dependent-Kinase inhibitor, Kinesin-spindle protein inhibitors, MEK1/2 inhibitors, AKT inhibitors and PIM-Kinase inhibitors. Expert opinion: Isatuximab, oprozomib, melflufen, venetoclax and filanesib seem to be the most promising agents with single agent activity. Nevertheless, lack of clinical activity as single agent does not imply clinical inefficacy in combination treatments.
2017
26
6
699
711
https://www.tandfonline.com/doi/abs/10.1080/13543784.2017.1324571?journalCode=ieid20
https://doi.org/10.1080/13543784.2017.1324571
AKT inhibitor; BCL-2 inhibitor; CDK inhibitor; MEK inhibitor; Multiple myeloma; PIM-Kinase inhibitor; alkylator; kinesin-spindle protein inhibitor; monoclonal antibody; proteasome inhibitor; single-agent
D'Agostino, Mattia; Salvini, Marco; Palumbo, Antonio; Larocca, Alessandra; Gay, Francesca
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] D'Agostino Salvini et al - Novel investigational drugs active as single agents in multiple myeloma.pdf

Accesso riservato

Descrizione: [Restricted access - Published vsn.] D'Agostino M, Salvini M et al. Expert Opin Investig Drugs . 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 May 8. © 2017 Informa UK Limited, trading as Taylor & Francis Group. Available at: https://www.tandfonline.com/doi/abs/10.1080/13543784.2017.1324571?journalCode=ieid20 | https://doi.org/10.1080/13543784.2017.1324571
Tipo di file: PDF EDITORIALE
Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
[Author Vsn] D'Agostino M Salvini M et al - 2017 - Exp Op Inv Drugs - Novel Investigational Drugs.pdf

Open Access dal 02/07/2018

Descrizione: Author's version. D'Agostino M, Salvini M et al. Expert Opin Investig Drugs . 2017 Jun;26(6):699-711. doi: 10.1080/13543784.2017.1324571. Epub 2017 May 8. © 2017 Informa UK Limited, trading as Taylor & Francis Group. The published version is available at: https://www.tandfonline.com/doi/abs/10.1080/13543784.2017.1324571?journalCode=ieid20 | https://doi.org/10.1080/13543784.2017.1324571 . When citing, please refer to the published version.
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 722.23 kB
Formato Adobe PDF
722.23 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1638049
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact